0:00
My name is Dr. Robert Hauser.
And I am Professor of
Neurology and Director
of the Parkinson's Disease
and Movement Disorder Center
at the University of South
Florida in Tampa, Florida.
I'll be talking about promising
medical therapies for Parkinson's
disease motor symptoms, including
motor fluctuations and dyskinesias.
0:22
I'll review antiparkinsonian
agents, including
A2a antagonists, new
levodopa preparations.
I'll mention an inhaled formulation
of apomorphine and safinamide,
a mixed MAO-B glutamate inhibitor.
I'll also talk about some
anti-dyskinetic medications
and development.
So all the medications that
I'll be talking about today
are investigational and are
not currently approved by FDA
for use in the United States or
by the regulatory authorities
in Europe.
0:56
A2a, or adenosine 2a
inhibitors, are technically
non-dopaminergic medications,
but they do interact
with the dopamine system.
In MPTP-lesioned
parkinsonian primates,
A2a inhibitors provide
motor benefit with little
or no development of dyskensia.
In addition, in MPTP-lesioned
levodopa-primed parkinsonian
animals who express dyskinesia, A2a
inhibitors improved motor function
when added to levodopa
without worsening dyskinesia.
So in these animal models
of both early and moderate
to advanced Parkinson's disease,
A2a inhibitors provide motor benefit
without causing or
worsening dyskinesia.
